Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Edward Gelmann
Member of the Graduate Faculty | Professor, Medicine
Medicine
Full Page
Overview
Research
More
Collaboration
(17)
Denise Roe
Mutual work: 8 Proposals﹒3 Grants
Collaboration Details
Anne Cress
Mutual work: 1 Proposal﹒1 Grant
Collaboration Details
William Montfort
Mutual work: 4 Proposals﹒1 Grant
Collaboration Details
Roberta Brinton
Mutual work: 1 Publication
Collaboration Details
Floyd Chilton
Mutual work: 1 Proposal
Collaboration Details
Page 1 of 4
Previous page
Next page
Grants
(17)
A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed O
Active
·
2024
·
$0 / $2.2M
·
External
Co-Investigator (COI)
prostate cancer,
clinical trial,
treatment comparison,
metastatic cancer,
hormone therapy
A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREG) in Patients with Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma
Active
·
2024
·
$625.4K
·
External
Principal Investigator (PI)
oncology,
clinical trial,
drug combination,
efficacy,
patient safety
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus In
Active
·
2024
·
$0 / $12.7K
·
External
Co-Investigator (COI)
clinical trials,
cancer treatment,
immunotherapy,
bladder cancer,
combination therapy
The Robert A.Winn Diversity in Clinical Trials: Career Development Award
Active
·
2023
·
$0 / $240K
·
External
Key Personnel (KP)
clinical trials,
diversity,
career development,
research,
healthcare disparities
DYRK1B Inhibition for Prostate Cancer
Active
·
2023
·
$145.8K / $153.5K
·
External
Principal Investigator (PI)
prostate cancer,
dyrk1b inhibition,
cancer treatment,
molecular targeting,
drug development
Page 1 of 4
Previous page
Next page
Publications
(17)
Recent
Data from CRISPR/Cas9-Mediated Point Mutation in i>Nkx3.1<i> Prolongs Protein Half-Life and Reverses Effects i>Nkx3.1<i> Allelic Loss
2023
crispr/cas9,
gene editing,
protein stability,
mutation,
gene expression
Androgen-targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer
2022
prostate cancer,
androgen-targeting,
gnrh agonist,
neurodegenerative disease,
therapeutics
CRISPR/Cas9-Mediated Point Mutation in Prolongs Protein Half-Life and Reverses Effects Allelic Loss
2020
genome editing,
protein stability,
genetic engineering,
molecular biology,
therapeutic development
Loss of PTEN Accelerates NKX3.1 Degradation to Promote Prostate Cancer Progression
2019
cancer,
genetics,
prostate,
tumor suppressor,
cell signaling
Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression
2018
prostate cancer,
tissue microarray,
annexin a7,
prognostic role,
cancer progression
Development, Evaluation, and Implementation of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate
2018
cancer research,
medical network,
prostate cancer,
epidemiology,
public health
Treatment of the Prostate in the Presence of Metastases: Lessons from Other Solid Tumors
2016
prostate cancer,
metastases,
solid tumors,
treatment,
lessons
Nkx3.1 controls the DNA repair response in the mouse prostate
2016
dna repair,
prostate cancer,
gene regulation,
mouse model,
cellular response
NKX3.1 Suppresses TMPRSS2-ERG Gene Rearrangement and Mediates Repair of Androgen Receptor-Induced DNA Damage
2015
prostate cancer,
gene regulation,
dna repair,
androgen receptor,
transcription factors
The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase
2015
cancer,
cell biology,
protein degradation,
kinase signaling,
tumor suppressor
